A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death

被引：5

作者：

Ray, Arghya ^{[1
,2
]}

Du, Ting ^{[1
,2
]}

Wan, Xueping ^{[1
,2
]}

Song, Yan ^{[1
,2
]}

Pillai, Sindhu C. ^{[1
,2
]}

Musa, Md. Abu ^{[1
,2
]}

Fang, Teng ^{[1
,2
]}

Moore, Jared ^{[3
]}

Blank, Brian ^{[3
]}

Du, Xiaohui ^{[3
]}

Chen, Xi ^{[3
]}

Warne, Robert ^{[3
]}

Sutimantanapi, Dena ^{[3
]}

Lui, Fang ^{[3
]}

Zavorotinskaya, Tatiana ^{[3
]}

Colas, Christophe ^{[3
]}

Friedman, Lori ^{[3
]}

Junttila, Melissa R. ^{[3
]}

Chauhan, Dharminder ^{[1
,2
]}

Anderson, Kenneth C. ^{[1
,2
]}

机构：

[1] Harvard Med Sch, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA

[3] ORIC Pharmaceut Inc, South San Francisco, CA USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

基金：

美国国家卫生研究院;

关键词：

T-CELLS; COMBINATION; CHECKPOINT; ADENOSINE; CANCER;

D O I：

10.1038/s41408-024-01019-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

center dot CD73 is the key ectoenzyme involved in the generation of AMP-derived adenosine, which contributes to immunosuppression in the MM BM milieu. center dot Blocking CD73 activity with a potent, selective, orally bioavailable CD73 inhibitor ORIC-533 decreases adenosine generation, overcomes immune suppression, and restores immune cell-mediated MM cell lysis. center dot Based on these preclinical studies, a multi-center clinical trial of ORIC-533 has been initiated in patients with relapsed refractory MM (NCT05227144).

引用

页数：6

共 25 条

[1] Promise of Immune Therapies in Multiple Myeloma
Anderson, Kenneth C.
[J]. JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (07) : 411 - +
[2] [Anonymous], 2021, Key Statistics About Multiple Myeloma
[3] Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, Luca
Blandizzi, Corrado
Pacher, Pal
Hasko, Gyoergy
[J]. NATURE REVIEWS CANCER, 2013, 13 (12) : 842 - 857
[4] Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
Buisseret, L.
Pommey, S.
Allard, B.
Garaud, S.
Bergeron, M.
Cousineau, I.
Ameye, L.
Bareche, Y.
Paesmans, M.
Crown, J. P. A.
Di Leo, A.
Loi, S.
Piccart-Gebhart, M.
Willard-Gallo, K.
Sotiriou, C.
Stagg, J.
[J]. ANNALS OF ONCOLOGY, 2018, 29 (04) : 1056 - 1062
[5] Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction
Burke, Brianna
Eden, Catherine
Perez, Cynthia
Belshoff, Alex
Hart, Spencer
Plaza-Rojas, Lourdes
Delos Reyes, Michael
Prajapati, Kushal
Voelkel-Johnson, Christina
Henry, Elizabeth
Gupta, Gopal
Guevara-Patino, Jose
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[6] Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients
Busch, A.
Zeh, D.
Janzen, V.
Muegge, L. -O.
Wolf, D.
Fingerhut, L.
Hahn-Ast, C.
Maurer, O.
Brossart, P.
von Lilienfeld-Toal, M.
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 177 (02) : 439 - 453
[7] Adenosinergic Signaling Alters Natural Killer Cell Functional Responses
Chambers, Andrea M.
Wang, Jiao
Lupo, Kyle B.
Yu, Hao
Lanman, Nadia M. Atallah
Matosevic, Sandro
[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
[8] Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Chauhan, Dharminder
Singh, Ajita V.
Brahmandam, Mohan
Carrasco, Ruben
Bandi, Madhavi
Hideshima, Teru
Bianchi, Giada
Podar, Klaus
Tai, Yu-Tzu
Mitsiades, Constantine
Raje, Noopur
Jaye, David L.
Kumar, Shaji K.
Richardson, Paul
Munshi, Nikhil
Anderson, Kenneth C.
[J]. CANCER CELL, 2009, 16 (04) : 309 - 323
[9] The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells
Da, Meihong
Chen, Luxia
Enk, Alexander
Ring, Sabine
Mahnke, Karsten
[J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
[10] Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Goerguen, Guellue
Samur, Mehmet K.
Cowens, Kristen B.
Paula, Steven
Bianchi, Giada
Anderson, Julie E.
White, Randie E.
Singh, Ahaana
Ohguchi, Hiroto
Suzuki, Rikio
Kikuchi, Shohei
Harada, Takeshi
Hideshima, Teru
Tai, Yu-Tzu
Laubach, Jacob P.
Raje, Noopur
Magrangeas, Florence
Minvielle, Stephane
Avet-Loiseau, Herve
Munshi, Nikhil C.
Dorfman, David M.
Richardson, Paul G.
Anderson, Kenneth C.
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (20) : 4607 - 4618

← 1 2 3 →